BioCentury

1:11 AM GMT, Sep 7, 2012
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Top Story

Merck KGaA, Symphogen in cancer deal

Symphogen A/S (Copenhagen, Denmark) granted Merck KGaA (Xetra:MRK) exclusive, worldwide rights to develop and commercialize cancer product Sym004.

Read the full 181 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.